The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
Open accessAbstract
BACKGROUND: The effect of intensified platelet inhibition for patients with unstable angina or myocardial infarction without ST-segment elevation who do not undergo revascularization has not been delineated. METHODS: In this double-blind, randomized trial, in a primary analysis involving 7243 patients under the age of 75 years receiving aspirin, we evaluated up to 30 months of treatment with prasugrel (10 mg daily) versus clopidogrel (75 mg daily). In a secondary analysis involving 2083 patients 75 years of age or older, we evaluated 5 mg of prasugrel versus 75 mg of clopidogrel. RESULTS: At a median follow-up of 17 months, the primary end point of death from cardiovascular causes, myocardial infarction, or stroke among patients under the age of 75 years occurred in 13.9% of the prasugrel group and 16.0% of the clopidogrel group (hazard ratio in the prasugrel group, 0.91; 95% confidence interval [CI], 0.79 to 1.05; P=0.21). Similar results were observed in the overall population. The prespecified analysis of multiple recurrent ischemic events (all components of the primary end point) suggested a lower risk for prasugrel among patients under the age of 75 years (hazard ratio, 0.85; 95% CI, 0.72 to 1.00; P=0.04). Rates of severe and intracranial bleeding were similar in the two groups in all age groups. There was no significant between-group difference in the frequency of nonhemorrhagic serious adverse events, except for a higher frequency of heart failure in the clopidogrel group. CONCLUSIONS: Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed. (Funded by Eli Lilly and Daiichi Sankyo; TRILOGY ACS ClinicalTrials.gov number, NCT00699998.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition to their initial events, such patients are at substantial risk for recurrent, potentially fatal events.”
From Effects of Icosapent Ethyl on Total Ischemic Events (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Prasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citationCox’s regression model for counting processes: A large sample study
Andersen, P. K., & Gill, R. D. (1982) · The Annals of Statistics · doi:10.1214/aos/1176345976 · Cited by 4,419
A Prospective Natural-History Study of Coronary Atherosclerosis
Stone, G. W., Maehara, A., Lansky, A. J., Bruyne, B. D., Cristea, E., Mintz, G. S., Mehran, R., McPherson, J., Farhat, N. Z., Marso, S. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1002358 · Cited by 3,301
Authors Task Force Members, Hamm, C. W., Bassand, J., Agewall, S., Bax, J. J., Boersma, E. H., Bueno, H., Caso, P., Dudek, D., Gielen, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr236 · Cited by 3,096
Self-citationClopidogrel for Coronary Stenting
Gurbel, P. A., Bliden, K. P., Hiatt, B. L., & O’Connor, C. M. (2003) · Circulation · doi:10.1161/01.cir.0000072771.11429.83 · Cited by 1,544
Self-citationHamm, C. W., Bassand, J., Agewall, S., Bax, J. J., Boersma, E. H., Bueno, H., Caso, P., Dudek, D., Gielen, S., Huber, K., et al. (2012) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2011.11.006 · Cited by 1,062
Self-citationThrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
Tricoci, P., Huang, Z., Held, C., Moliterno, D. J., Armstrong, P. W., de Werf, F. V., White, H. D., Aylward, P. E., Wallentin, L. C., Chen, E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1109719 · Cited by 756
Self-citationWright, R. S., Anderson, J. L., Adams, C. D., Bridges, C. R., Casey, D. E., Ettinger, S. M., Fesmire, F. M., Ganiats, T. G., Jneid, H. M., Lincoff, A. M., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.011 · Cited by 513
Roe, M. T., Messenger, J. C., Weintraub, W. S., Cannon, C. P., Fonarow, G. C., Dai, D., Chen, A. Y., Klein, L. W., Masoudi, F. A., McKay, C. R., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.008 · Cited by 447
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 401–500 of 873
Marquis‐Gravel, G., Neely, M. L., Valgimigli, M., Costa, F., Klaveren, D. V., Altner, R., Bhatt, D. L., Armstrong, P. W., Fox, K. A. A., White, H. D., et al. (2020) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.120.006582 · Cited by 10
Self-citationHyperactivity and Pro-inflammatory Functions of Platelets in Diabetes
Greaves, J., & Pula, G. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl26190 · Cited by 10
European Society of Cardiology (ESC) Congress Report From Munich 2012
Ozaki, Y. (2012) · Circulation Journal · doi:10.1253/circj.cj-66-0051 · Cited by 9
Varian, F., Parker, W. A., Fotheringham, J., & Storey, R. F. (2022) · Platelets · doi:10.1080/09537104.2022.2154330 · Cited by 11
Aging and Antithrombotic Treatment
Valeriani, E., Bartimoccia, S., Pignatelli, P., & Pastori, D. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0373 · Cited by 11
Lucà, F., Pavan, D., Gulizia, M. M., Manes, M. T., Abrignani, M. G., Benedetto, F. A., Bisceglia, I., Brigido, S., Caldarola, P., Calvanese, R., et al. (2024) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae034 · Cited by 10
Combined Antiplatelet Therapy: Still a Sweeping Combination in Cardiology
Manolis, A. S., Manolis, T. A., Papadimitriou, P., Koulouris, S., & Melita, H. (2013) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/1871525711311020009 · Cited by 9
Serebruany, V. L., Tomek, A., Pokov, A. N., & Kim, M. H. (2015) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2015.1101343 · Cited by 9
Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy
Doll, J. A., Li, S., Chiswell, K., Roe, M. T., Kosiborod, M., Scirica, B. M., & Wang, T. Y. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx255 · Cited by 9
Self-citationBueno, H., Pocock, S., Medina, J., Danchin, N., Annemans, L., Licour, M., Gregson, J., Vega, A. M., & de Werf, F. V. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2016.11.046 · Cited by 9
Mischie, A. N., Andrei, C. L., Sinescu, C. J., Bajraktari, G., Ivan, E., Chatziathanasiou, G., & Schiariti, M. S. (2017) · PubMed Central · doi:10.11909/j.issn.1671-5411.2017.07.006 · Cited by 9
Non-ST Elevation Myocardial Infarction: Diagnosis and Management
Alahmad, Y., & Ali, M. T. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.76241 · Cited by 9
Jaffer, I., & Weitz, J. I. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00149-9 · Cited by 9
Antithrombotika und Antihämorrhagika
Hein, L. (2011) · Springer eBooks · doi:10.1007/978-3-642-21992-4_15 · Cited by 9
Basra, S. S., Virani, S. S., Paniagua, D. E., Kar, B., & Jneid, H. M. (2014) · Cardiology Clinics · doi:10.1016/j.ccl.2014.04.010 · Cited by 10
Cornel, J. H., Lópes, R. D., James, S. K., Stevens, S. R., Neely, M. L., Liaw, D., Miller, J., Mohan, P., Amerena, J. V., Raev, D. H., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2014.12.022 · Cited by 9
Self-citationNovel Antiplatelet and Anticoagulant Agents in the Cardiac Care Unit
Garg, V., & Halperin, J. L. (2013) · Cardiology Clinics · doi:10.1016/j.ccl.2013.07.001 · Cited by 9
Husted, S. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s75024 · Cited by 9
Type 2 Diabetes and ADP Receptor Blocker Therapy
Samoš, M., Fedor, M., Kovář, F., Mokáň, M., Bolek, T., Galajda, P., Kubisz, P., & Mokáň, M. (2015) · Journal of Diabetes Research · doi:10.1155/2016/6760710 · Cited by 9
Bueno, H., Pocock, S., Medina, J., Danchin, N., Annemans, L., Licour, M., Gregson, J., Vega, A. M., & de Werf, F. V. (2017) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2016.12.031 · Cited by 9
Dual-antiplatelet Therapy Guidelines and Implications for Perioperative Management
Stawiarski, K. M., Kataria, R., Bravo, C., Villablanca, P., Mohananey, D., Narasimhan, S., & Ramakrishna, H. (2017) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2017.06.033 · Cited by 9
Menozzi, A., Servi, S. D., Rossini, R., Ferlini, M., Lina, D., Abrignani, M. G., Capranzano, P., Carrabba, N., Galvani, M., Marchese, A., et al. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.066 · Cited by 9
Price, M. J. (2012) · JAMA · doi:10.1001/jama.2012.34011 · Cited by 9
Chen, S., Qiang, J., Zhang, Y., Zhao, B., Tian, R., Yuan, T., Li, M., Li, M., Li, Y., Zhu, H., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1091933 · Cited by 9
Ko, D. T., Al-Lamee, R. K., Bikdeli, B., Cohen, D. J., Januzzi, J. L., Sawano, M., Spatz, E. S., & You, S. C. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.04.045 · Cited by 9
New Antiplatelet Agents and the Role of Platelet Function Testing in Acute Coronary Syndromes
Sinhal, A. R., & Aylward, P. E. (2013) · Clinical Therapeutics · doi:10.1016/j.clinthera.2013.07.429 · Cited by 8
Self-citationPrise en charge du risque hémorragique associé aux agents antiplaquettaires
Martin, A., Houssany-Pissot, S., Zlotnik, D., Taylor, G., & Godiér, A. (2017) · La Revue de Médecine Interne · doi:10.1016/j.revmed.2017.01.013 · Cited by 8
Actualización en cardiopatía isquémica y cuidados críticos cardiológicos
Jiménez‐Candil, J., Dı́az-Castro, Ó., Barrabés, J. A., de la Villa, B. G., Peris, V. B., López‐Palop, R., Fernández‐Ortíz, A., & Martínez‐Sellés, M. (2013) · Revista Española de Cardiología · doi:10.1016/j.recesp.2012.10.019 · Cited by 8
Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary Syndromes
Russo, I., Brookles, C. G., Barale, C., Melchionda, E., Mousavi, A. H., Biolè, C., Chinaglia, A., & Bianco, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25073981 · Cited by 11
DiNicolantonio, J. J., & Serebruany, V. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-02-0142 · Cited by 8
Efficacy and safety of prasugrel in acute coronary syndrome patients
Nanau, R. M., Delzor, F., & Neuman, M. G. (2014) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2014.03.005 · Cited by 8
Cho, J. R., Desai, B., Haas, M. J., Rollini, F., Franchi, F., Muñiz‐Lozano, A., Tello‐Montoliu, A., Ferrante, E., Guzmán, L. A., Bass, T. A., et al. (2013) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-013-9530-8 · Cited by 8
Natarajan, P., Jaffer, F. A., Sabatine, M. S., & Sabatine, M. S. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4483-0_3 · Cited by 7
Recovery Free of Heart Failure After Acute Coronary Syndrome and Coronary Revascularization
Falkenham, A., Saraswat, M. K., Wong, C., Gawdat, K., Myers, T. L., Begum, J., Buth, K. J., Haidl, I. D., Marshall, J. S., & Légaré, J. (2017) · ESC Heart Failure · doi:10.1002/ehf2.12197 · Cited by 7
Dual Antiplatelet Therapy in Patients with High Cardiovascular Risk
Espinoza, C., & Mukherjee, D. (2021) · Heart International · doi:10.17925/hi.2021.15.1.26 · Cited by 8
Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome
Towashiraporn, K., & Krittayaphong, R. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s289295 · Cited by 10
Practical experience with ticagrelor: an Australian and New Zealand perspective
Harding, S. A., van Gaal, W. J., Schrale, R. G., Gunasekara, A. P., Amerena, J. V., Mussap, C., & Aylward, P. E. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1058247 · Cited by 8
Self-citationPercutaneous coronary intervention in diabetic patients: should choice of stents be influenced?
Harskamp, R. E., & Park, D. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.13.38 · Cited by 8
Chen, Y., Zhang, Y., Tang, Y., Huang, X., & Xie, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078549 · Cited by 8
Oral Antiplatelet Therapy in Acute Coronary Syndromes: Recent Developments
Zeymer, U. (2013) · Cardiology and Therapy · doi:10.1007/s40119-013-0011-6 · Cited by 8
Unclassified Pleomorphic and Spindle Cell Pulmonary Neoplasm with Brain Metastases after Prasugrel
Serebruany, V. L., DiNicolantonio, J. J., Can, M. M., & Goto, S. (2013) · Cardiology · doi:10.1159/000346382 · Cited by 8
Latest developments in anticoagulant drug discovery
Broussalis, E., Anna, W., Trinka, E., Mutzenbach, J. S., & Killer‐Oberpfalzer, M. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.02.011 · Cited by 8
Lee, D. H., Kim, M. H., Guo, L. Z., Park, M. K., & Yi, S. (2014) · Korean Circulation Journal · doi:10.4070/kcj.2014.44.6.386 · Cited by 8
Choi, J. H., Cho, J. R., Park, S. M., Shaha, K. B., Pierres, F., Tserendavaa, S., Chun, K. J., Kang, M.-K., Choi, S., & Lee, N. (2017) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.5.959 · Cited by 8
Iqbal, J., Widmer, R. J., & Gersh, B. J. (2017) · EuroIntervention · doi:10.4244/eij-d-17-00463 · Cited by 8
Butala, N. M., Jaffer, F. A., & Sabatine, M. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-45792-1_4 · Cited by 10
Reanalysis or redefinition of the hypothesis?
Ciolino, J. D., & Carter, R. E. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu311 · Cited by 8
Hamid, T., & Zaman, M. (2016) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000194 · Cited by 6
Luca, L. D., Colivicchi, F., Gulizia, M. M., Pugliese, F. R., Ruggieri, M. P., Musumeci, G., Cibinel, G. A., & Romeo, F. (2017) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux013 · Cited by 7
Antiplatelet therapy for coronary artery disease in 2023: current status and future prospects
Chandiramani, R., Spirito, A., Johnson, J. W., Mehta, A., Vogel, B., FAILLACE, R. T., & Mehran, R. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2201437 · Cited by 8
Anticoagulation and antiplatelet therapy in acute coronary syndromes
Singh, D., Gupta, K., & Vacek, J. L. (2014) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.81a.13016 · Cited by 7
Dual antiplatelet therapy in patients with diabetes mellitus: special considerations
Capranzano, P., & Capodanno, D. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.13.3 · Cited by 7
High platelet reactivity – the challenge of prolonged anticoagulation therapy after ACSI
Brouwer, M. A., Verheugt, F. W. A., & Focks, J. (2013) · Thrombosis and Haemostasis · doi:10.1160/th12-08-0582 · Cited by 7
Amsterdam, E. A., WENGER, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H. M., Kelly, R. F., Kontos, M. C., et al. (2014) · Cited by 7
Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients
Sabouret, P. F., Savage, M. P., Fischman, D. L., & Costa, F. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00414-0 · Cited by 10
Falster, M. O., Schaffer, A. L., Wilson, A., Nasis, A., Jorm, L. R., Hay, M., Leeb, K., Pearson, S., & Brieger, D. B. (2020) · Internal Medicine Journal · doi:10.1111/imj.15036 · Cited by 7
Antithrombotic Therapy in Elderly Patients with Acute Coronary Syndromes
Bonanad, C., Claramunt, F. E., García‐Blas, S., Ayesta, A., Díez‐Villanueva, P., Pérez-Rivera, J.-Á., Ferreiro, J. L., Cànoves, J., López-Fornás, F. J., Ariza‐Solé, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11113008 · Cited by 7
Lahu, S., Scalamogna, M., Ndrepepa, G., Menichelli, M., Valina, C. M., Hemetsberger, R., Witzenbichler, B., Bernlochner, I., Joner, M., Xhepa, E., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.027257 · Cited by 7
Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary Syndromes
Rocca, B., & Husted, S. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0359-0 · Cited by 7
Point of care platelet function testing in routine neurointerventional care is unjustified
Chandra, R. V. (2013) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2013-010808 · Cited by 7
Jackson, L. R., Piccini, J. P., Cyr, D. D., Roe, M. T., Neely, M. L., Martínez, F. A., Lüscher, T. F., Lópes, R. D., Winters, K. J., White, H. D., et al. (2016) · Clinical Cardiology · doi:10.1002/clc.22562 · Cited by 7
Self-citationAntithrombotic Therapy for ACS in Elderly Patients
Roule, V., Blanchart, K., Humbert, X., Legallois, D., Lemaître, A., Milliez, P., Beygui, F., & Alexandre, J. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6761-y · Cited by 7
Dual antiplatelet therapy in patients with an acute coronary syndrome: up to 12 months and beyond
Pareek, M., & Bhatt, D. L. (2018) · European Heart Journal Supplements · doi:10.1093/eurheartj/sux042 · Cited by 7
Self-citationKaul, P., Alexander, K. P., Ohman, E. M., Savu, A., Roe, M. T., Goodman, S. G., Fox, K. A. A., White, H. D., Prabhakaran, D., Hochman, J. S., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.12.035 · Cited by 7
Self-citationLin, Y., Cai, Z., Dong, S., Liu, H., Pang, X., Chen, Q., Yuan, J., & Geng, Q. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.992376 · Cited by 8
Management Strategies for Clopidogrel Hypersensitivity
Beavers, C. J., Carris, N. W., & Ruf, K. M. (2015) · Drugs · doi:10.1007/s40265-015-0414-x · Cited by 7
Excessive Long-Term Platelet Inhibition With Prasugrel or Ticagrelor and Risk of Infection
Kipshidze, N. N., Platonova, E., DiNicolantonio, J. J., Kuliczkowski, W., & Serebruany, V. L. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3182a4ef6f · Cited by 7
Doraiswamy, V. A., Slepian, M. J., Gesheff, M. G., Tantry, U. S., & Gurbel, P. A. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.2013.827469 · Cited by 7
Self-citationSirker, A., Kwok, C. S., Kontopantelis, E., Johnson, T., Freeman, P. M., de Belder, M., Ludman, P., Zaman, A., & Mamas, M. A. (2018) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.27493 · Cited by 7
Non-ST-Segment Elevation Acute Coronary Syndrome
Montalescot, G. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.10.010 · Cited by 7
Leonardi, S., Camporotondo, R., Ferrari, G. M. D., & Iannopollo, G. (2014) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s39216 · Cited by 6
Antiplatelet therapy for treatment of coronary artery disease in older patients
Fischer, Q., Pham, V., Seret, G., Brami, P., Picard, F. A., & Varenne, O. (2024) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2024.02.008 · Cited by 8
Recent advances in antithrombotic therapy after acute coronary syndrome
Matteau, A., & Bhatt, D. L. (2013) · Canadian Medical Association Journal · doi:10.1503/cmaj.130506 · Cited by 6
Self-citationYe, Y., Xie, H., Zeng, Y., Zhao, X., Tian, Z., & Zhang, S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090986 · Cited by 6
Sun, J., Yang, G.-H., Liu, J.-X., Liu, X.-L., Ma, Y., Lu, R., Zhang, Y., Chen, S., Zhao, J., Ji, W., et al. (2017) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029617726600 · Cited by 6
Lam, A. S. M., Yan, B. P.-Y., & Lee, V. W. Y. (2021) · Clinical Cardiology · doi:10.1002/clc.23653 · Cited by 6
Antiplatelet Therapy in Atherothrombotic Diseases: Similarities and Differences Across Guidelines
Jourdi, G., Marquis‐Gravel, G., Martin, A., Lordkipanidzé, M., Godiér, A., & Gaussem, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.878416 · Cited by 7
Antiplatelet Therapy in Coronary Artery Disease: Now and Then
Tscharre, M., & Gremmel, T. (2022) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0042-1758821 · Cited by 5
Monitoring Aspirin and Clopidogrel Response: Testing Controversies and Recommendations
Karathanos, A., & Geisler, T. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0022-y · Cited by 6
Novel Antiplatelet Agent Use for Acute Coronary Syndrome in the Emergency Department: A Review
Curial, M., Nath, E., & Lang, E. (2013) · Cardiology Research and Practice · doi:10.1155/2013/127270 · Cited by 6
Chen, K. (2015) · Medical Science Monitor · doi:10.12659/msm.893914 · Cited by 6
Forbidden Fruit: On the Analysis of Recurrent Events in Randomized Clinical Trials
Diamond, G. A., & Kaul, S. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.01.310 · Cited by 6
Recent advances in antithrombotic treatment for acute coronary syndromes
Howard, J. P., Antoniou, S., Jones, D. A., & Wragg, A. (2014) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.923306 · Cited by 6
Blatt, A., Kalmanovich, E., Karny-Rahkovich, O., Brener, S., Shlezinger, M., Nir, S., Vered, Z., Hod, H., Goldenberg, I., & Elbaz‐Greener, G. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.03.054 · Cited by 6
Usta, C., & Bedel, H. A. (2017) · PubMed Central · doi:10.11909/j.issn.1671-5411.2017.07.005 · Cited by 6
Jin, C. D., Kim, M. H., Guo, L. Z., Jin, E., Shin, E., Ann, S. H., Cho, Y., Park, J. S., Kim, S., & Lee, M. S. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.01.058 · Cited by 6
Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada
Lordkipanidzé, M., Marquis‐Gravel, G., Tanguay, J., Mehta, S. R., & So, D. Y. F. (2020) · CJC Open · doi:10.1016/j.cjco.2020.11.021 · Cited by 6
A Hierarchical Approach to Multi-Event Survival Analysis
Tjandra, D., He, Y., & Wiens, J. (2021) · Proceedings of the AAAI Conference on Artificial Intelligence · doi:10.1609/aaai.v35i1.16138 · Cited by 6
Saito, T., Fujisaki, T., Aikawa, T., Kampaktsis, P. Ν., Malik, A. H., Briasoulis, Α., Takagi, H., Wiley, J., Slipczuk, L. N., & Kuno, T. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131157 · Cited by 6
Quatromoni, N., Tuteja, S., Kolansky, D. M., Matthai, W., & Giri, J. S. (2015) · Current Atherosclerosis Reports · doi:10.1007/s11883-015-0501-1 · Cited by 6
Naik, B. I., Keeley, E. C., Gress, D. R., & Zuo, Z. (2014) · Anesthesiology · doi:10.1097/aln.0000000000000350 · Cited by 6
Cornel, J. H., Ohman, E. M., Neely, B., Jakubowski, J. A., Bhatt, D. L., White, H. D., Ardissino, D., Fox, K. A. A., Prabhakaran, D., Armstrong, P. W., et al. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.116.003977 · Cited by 6
Self-citationArmstrong, P. W., & Westerhout, C. M. (2013) · Circulation · doi:10.1161/circulationaha.112.000627 · Cited by 6
Self-citationBjarnason‐Wehrens, B., & Tamulevičiūtė-Prascienė, E. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab063 · Cited by 6
A history of the development of dual antiplatelet therapy for coronary artery disease
Coughlan, J. J., Durand, R., Birrane, J. P., Blackburne, B., Kastrati, A., & Byrne, R. A. (2025) · Journal of Thrombosis and Haemostasis · doi:10.1016/j.jtha.2025.06.011 · Cited by 6
TRILOGY ACS: prasugrel of benefit only after angiography?
Swaminathan, R. V., & Feldman, D. N. (2013) · The Lancet · doi:10.1016/s0140-6736(13)61640-2 · Cited by 5
The Challenge of Antiplatelet Therapy in Patients with Atrial Fibrillation and Heart Failure
Guo, Y., Lip, G. Y. H., & Apostolakis, S. Z. (2012) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-012-9427-y · Cited by 5
Recent Advances in the Development of P2Y12 Receptor Antagonists as Antiplatelet Agents
Caldwell, A. T., & Watkins, E. B. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00007-9 · Cited by 5
Camm, A. J., & Fox, K. A. A. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1467885 · Cited by 5
Self-citationMo, F., Li, J., Yan, Y., Wu, W., & Lai, S. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s166544 · Cited by 5
Metadata
- Authors
- Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., Ardissino, D., Nicolau, J. C., Boden, W. E., Gurbel, P. A., Ruzyllo, W., Dalby, A. J., McGuire, D. K., Leiva-Pons, J. L., Parkhomenko, A., Gottlieb, S., Topacio, G. O., Hamm, C., Pavlides, G., Goudev, A. R., Oto, A., Tseng, C.-D., Merkely, B., Gasparovic, V., Corbalan, R., Cinteză, M., McLendon, R. C., Winters, K. J., Brown, E. B., Lokhnygina, Y., Aylward, P. E., Huber, K., Hochman, J. S., & Ohman, E. M.
- Affiliations
- Duke Medical Center (US)
- University of Alberta (CA)
- Duke University (US)
- St. Michael's Hospital (CA)
- Brigham and Women's Hospital (US)
- University of Copenhagen (DK)
- National Taiwan University (TW)
- Eli Lilly (United States) (US)
- Flinders University (AU)
- ORCID
- Roe, Matthew T.
- Armstrong, Paul W.
- Fox, Keith A.A.
- White, Harvey D.
- Prabhakaran, Dorairaj
- Goodman, Shaun G.
- Cornel, Jan H.
- Bhatt, Deepak L.
- Clemmensen, Peter
- Ardissino, Diego
- Boden, William E.
- Gurbel, Paul A.
- McGuire, Darren K.
- Leiva-Pons, Jose L.
- Parkhomenko, Alexander
- Gottlieb, Shmuel
- Hamm, Christian
- Goudev, Assen R.
- Oto, Ali
- Aylward, Philip E.
- Huber, Kurt
- Hochman, Judith S.
- Ohman, E. Magnus
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-10-04
- Volume
- 367
- Issue
- 14
- Pages
- 1297-1309
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2109577952
- Cited by
- 874
- References
- 18
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 14 · 2023: 31 · 2022: 43 · 2021: 49 · 2020: 58 · 2019: 53 · 2018: 70 · 2017: 92 · 2016: 71 · 2015: 91 · 2014: 114 · 2013: 124 · 2012: 20
- FWCI
- 71.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Scientific Electronic Library Online (São Paulo Research Foundation, Latin American and Caribbean Center on Health Sciences Information, Conselho Nacional de Desenvolvimento Científico e Tecnológico) (publishedVersion)
- Trakya University's Institutional Open Access System (Trakya University) (submittedVersion, other-oa)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
- ORBi (University of Liège) (submittedVersion)
- Edinburgh Research Explorer (University of Edinburgh) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Amylin Pharmaceuticals
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Helsinn
- Boston Scientific Corporation
- Boston VA Research Institute
- Regeneron Pharmaceuticals
- Amarin Corporation
- Medicines Company
- Regado Biosciences
- Eisai
- Astellas Pharma
- Servier
- Genentech
- Janssen Pharmaceuticals
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- prasugrel, clopidogrel, acute coronary syndrome, non-ST-elevation myocardial infarction, unstable angina, platelet aggregation inhibition, antiplatelet therapy, bleeding risk, heart failure, cardiovascular mortality, stroke, elderly patients
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Angina, Unstable, Aspirin, Cardiovascular Diseases, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Ticlopidine, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
